ClinConnect ClinConnect Logo
Search / Trial NCT06914375

Effect of Lentils and Chickpeas on Gut Microbiome and Metabolic Health

Launched by FLORIDA STATE UNIVERSITY · Apr 4, 2025

Trial Information

Current as of July 22, 2025

Recruiting

Keywords

Fiber Gut Microbiome Pulses Chickpea Lentil Young Adults Transit Time Prebiotic Metagenomic Metabolic Health

ClinConnect Summary

This clinical trial is studying how eating lentils and chickpeas every day for eight weeks can affect gut health and overall metabolic health in healthy young adults. The researchers want to see if these foods can help improve the balance of good bacteria in the gut and reduce inflammation, which can contribute to better health. Participants in the study will either eat whole-cooked lentils or chickpeas daily while continuing their normal diet, or they will not eat any pulses (the group that does not eat lentils or chickpeas is called the control group).

To join the study, you need to be between 18 and 30 years old and be able to read and speak English. Some people, such as those with certain health conditions or those who have used specific medications recently, won’t be eligible to participate. If you decide to join, you'll be asked to keep track of how well you can add these foods to your daily meals for two months. The study is currently recruiting participants, and it’s a great opportunity to explore how these nutritious foods can impact your gut and overall health!

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Between 18 and 30 years old
  • Ability to speak and read in English
  • Exclusion Criteria:
  • Intake of antibiotics in the last 3 months
  • Intake of pre/pro/postbiotics in the last 3 months
  • Current or past (within the last 6 months) user of tobacco, marijuana, or E-cigarette products
  • Cardiovascular disease (heart failure, hypertension, hyper/dyslipidemia, past myocardial infarction)
  • Gastrointestinal disease (ulcerative colitis, Crohn's disease, diverticulosis, peptic ulcers, small intestinal bacterial overgrowth, fistulas, suspected or known gastric strictures, gastritis, radiation enteritis, GI bleeding, gastric bezoar, recent GI surgery in the last 3 months, etc..),
  • Neurological disorders (multiple sclerosis, meningitis, recent stroke) or endocrine disorders (uncontrolled thyroid disorders, growth hormone disorders, adrenal gland disorders, uncontrolled or insulin dependent diabetes - A1C \> 9%).
  • Food allergy to study foods (pulses or soy, milk, peanuts, tree nuts)
  • Regular consumption of pulses (\>1 cup/wk for males; \>0.5 cup/wk for females)
  • Current heavy alcohol use (≥ 15 drinks / week for men, ≥ 8 drinks / week for women)
  • Class 3 Obesity (BMI \> 40 kg/m2)
  • Known to be currently pregnant (self-disclosed).

About Florida State University

Florida State University (FSU) is a prestigious public research institution located in Tallahassee, Florida, known for its commitment to advancing knowledge and innovation in various fields, including health sciences. As a clinical trial sponsor, FSU leverages its extensive academic resources and expertise to conduct rigorous research aimed at improving patient outcomes and contributing to the medical community. The university fosters a collaborative environment that brings together multidisciplinary teams to design, implement, and analyze clinical studies, ensuring adherence to the highest ethical and scientific standards. Through its clinical trials, FSU aims to address critical health challenges and translate research findings into practical applications that benefit society.

Locations

Tallahassee, Florida, United States

Patients applied

0 patients applied

Trial Officials

Ravinder Nagpal, Ph.D.

Principal Investigator

Florida State University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported